Harris is a urologic oncologist with UroPartners LLC in Chicago, Illinois.
Letter: Declassifying Gleason 6 as a cancer would do more harm than good
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy